Related Experiment Video

Updated: Aug 11, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

Eva Giesen1, Lucia B Jilaveanu1, Fabio Parisi2

  • 1Yale Cancer Center, Yale University School of Medicine, New Haven, CT, U.S. These authors contributed equally to this work.

Oncotarget
|June 28, 2014
PubMed
Abstract

Insights

NY-ESO-1 is expressed in a subset of renal cell carcinomas (RCC), particularly clear cell types. Expression is higher in metastatic sites, suggesting this antigen is a potential target for novel immunotherapies in advanced RCC.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Novel immunotherapies targeting tumor-specific antigens are under development.
  • The cancer-testis antigen NY-ESO-1 is a potential target for these therapies.
  • NY-ESO-1 targeting approaches have not been evaluated in renal cell carcinoma (RCC).

Purpose of the Study:

  • To determine the expression of NY-ESO-1 in renal cell carcinoma (RCC).
  • To assess the potential of NY-ESO-1 as a target for immune therapies in RCC.
  • To evaluate NY-ESO-1 expression concordance between primary and metastatic RCC sites.

Main Methods:

  • Tissue microarrays with over 300 RCC cases and adjacent normal renal tissue were used.
  • Quantitative immunofluorescence was employed to determine NY-ESO-1 expression.
  • NY-ESO-1 expression was studied in 35 matched primary and metastatic RCC specimens.

Main Results:

  • NY-ESO-1 was highly expressed in a subset of RCCs.
  • Expression was significantly higher in primary RCC than in normal renal tissue (P<0.0001).
  • Clear cell RCC showed higher expression than papillary RCC (P<0.0001), and metastatic sites had higher expression than primary sites (P=0.0018).

Conclusions:

  • Aberrant NY-ESO-1 expression in clear cell RCC supports its investigation as a therapeutic target.
  • Higher expression in metastatic sites and discordance between primary and metastatic tumors suggest patient selection should be based on metastatic site expression.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K
Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

7.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.